OncoCyte Co. (NASDAQ:OCX) Shares Bought by Pura Vida Investments LLC

Pura Vida Investments LLC raised its position in shares of OncoCyte Co. (NASDAQ:OCX) by 32.1% in the 4th quarter, Holdings Channel reports. The firm owned 654,451 shares of the company’s stock after acquiring an additional 159,106 shares during the period. OncoCyte accounts for approximately 4.9% of Pura Vida Investments LLC’s holdings, making the stock its 9th largest position. Pura Vida Investments LLC’s holdings in OncoCyte were worth $1,558,000 as of its most recent SEC filing.

Separately, FNY Investment Advisers LLC grew its position in OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company’s stock worth $117,000 after acquiring an additional 6,481 shares during the last quarter. 55.35% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other OncoCyte news, CFO Andrea S. James bought 97,561 shares of the business’s stock in a transaction on Friday, February 7th. The stock was purchased at an average price of $2.05 per share, for a total transaction of $200,000.05. Following the completion of the transaction, the chief financial officer now directly owns 151,231 shares of the company’s stock, valued at $310,023.55. This trade represents a 181.78 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Patrick W. Smith purchased 1,077,600 shares of the stock in a transaction dated Friday, February 7th. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $2,209,080.00. Following the transaction, the insider now owns 2,872,671 shares of the company’s stock, valued at approximately $5,888,975.55. This trade represents a 60.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 1,185,625 shares of company stock valued at $2,430,510. Company insiders own 1.58% of the company’s stock.

OncoCyte Trading Down 0.3 %

Shares of OCX stock opened at $3.21 on Friday. OncoCyte Co. has a 12 month low of $1.92 and a 12 month high of $4.75. The firm has a market capitalization of $56.02 million, a PE ratio of -0.73 and a beta of 0.79. The firm has a fifty day simple moving average of $2.79 and a two-hundred day simple moving average of $2.72.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Monday, March 24th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.88. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.16 million. On average, equities analysts predict that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on OCX. Needham & Company LLC reiterated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a research report on Tuesday, March 25th. Lake Street Capital began coverage on shares of OncoCyte in a research report on Friday. They set a “buy” rating and a $5.00 target price on the stock. StockNews.com started coverage on shares of OncoCyte in a report on Monday, January 13th. They set a “sell” rating on the stock. Finally, Stephens reaffirmed an “equal weight” rating and set a $4.00 target price on shares of OncoCyte in a report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, OncoCyte has an average rating of “Hold” and a consensus target price of $4.56.

OncoCyte Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.